NEW YORK (GenomeWeb News) — Compendia Bioscience yesterday said it has won a $2.4-million SBIR Fast Track Award from the National Cancer Institute to help it further develop its Oncomine Professional technology.
Oncomine, designed for biomarker and therapeutic target discovery, validation, and prioritization, combines more than 20,000 cancer transcriptome profiles with an analysis engine and a web application to mine and visualize data, Compendia said.
The money for the project, called "Development of Oncomine Professional as a Platform for Biopharmaceutical Research and Development,” also results in Compendia co-founder Dan Rhodes being named CEO of the company. He will also serve as the principal investigator for the project.
Current CEO John Freshley will remain with the company as chief business officer overseeing sales, marketing, and corporate development, Compendia said.